1. pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy.
    Jin Qu et al, 2017, Acta Biomater CrossRef
  2. null
    Anfal Jasim et al, 2017 CrossRef
  3. null
    Muhammad Raza Shah et al, 2017 CrossRef
  4. Size Tunable Core Crosslinked Micelles from HPMA-Based Amphiphilic Block Copolymers
    Stefan Kramer et al, 2017, Macromol. Chem. Phys. CrossRef
  5. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
    YAN-JUN ZHONG et al, 2013 CrossRef
  6. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection
    Az Alddien Natfji et al, 2017, Journal of Pharmaceutical Sciences CrossRef
  7. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment
    Chun Y. Wong et al, 2017, Journal of Controlled Release CrossRef
  8. Polymer therapeutics and the EPR effect
    Hiroshi Maeda, 2017, Journal of Drug Targeting CrossRef
  9. FRET Imaging of Enzyme-Responsive HPMA Copolymer Conjugate.
    Rui Zhang et al, 2017, Macromol Biosci CrossRef
  10. Doxorubicin: nanotechnological overviews from bench to bedside.
    Maximiliano Cagel et al, 2017, Drug Discov Today CrossRef
  11. null
    S.P. Egusquiaguirre et al, 2016 CrossRef
  12. Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy.
    Ping Zhong et al, 2016, Biomacromolecules CrossRef
  13. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
    Karel Ulbrich et al, 2016, Chem. Rev. CrossRef
  14. Rethinking cancer nanotheranostics.
    Hongmin Chen et al, 2017, Nat Rev Mater CrossRef
  15. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
    Esther Tahover et al, 0 CrossRef
  16. Direct Cytoplasmic Delivery and Nuclear Targeting Delivery of HPMA-MT Conjugates in a Microtubules Dependent Fashion.
    Jiaju Zhong et al, 2016, Mol Pharm CrossRef
  17. null
    Dalit Landesman-Milo et al, 2016 CrossRef
  18. Antibody-targeted biodegradable nanoparticles for cancer therapy.
    Vahid Heravi Shargh et al, 2016, Nanomedicine (Lond) CrossRef
  19. αvβ3 Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo.
    Ping Zhong et al, 2017, J Control Release CrossRef
  20. Developments and future clinical outlook of taxane nanomedicines.
    Benoit Louage et al, 2017, J Control Release CrossRef
  21. Clinical advances of nanocarrier-based cancer therapy and diagnostics.
    Edurne Luque-Michel et al, 2017, Expert Opin Drug Deliv CrossRef
  22. Nanomedicine as an emerging platform for metastatic lung cancer therapy
    Dalit Landesman-Milo et al, 2015, Cancer Metastasis Rev CrossRef
  23. A novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin.
    Yu Gao et al, 2017, Nanoscale CrossRef
  24. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging.
    Eva Koziolová et al, 2017, Nanoscale CrossRef
  25. Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery.
    Min Liu et al, 2016, J Control Release CrossRef
  26. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Edgar Pérez-Herrero et al, 2015, Eur J Pharm Biopharm CrossRef
  27. Status and trends in the development of clinical diagnostic agents.
    Tatjana Opacic et al, 2017, Wiley Interdiscip Rev Nanomed Nanobiotechnol CrossRef
  28. Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents
    Raquel De Souza et al, 2015, Journal of Controlled Release CrossRef
  29. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.
    Andreas Wicki et al, 2015, J Control Release CrossRef
  30. Preclinical safety assessments of nano-sized constructs on cardiovascular system toxicity: A case for telemetry.
    Hoay Yan Cheah et al, 2017, J Appl Toxicol CrossRef
  31. Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats.
    Hoay Yan Cheah et al, 2017, Nanotoxicology CrossRef
  32. Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents
    Raul C Maranhão et al, 2017, Expert Opinion on Drug Delivery CrossRef
  33. Combination antitumor therapy with targeted dual-nanomedicines
    Wenbing Dai et al, 2017, Advanced Drug Delivery Reviews CrossRef
  34. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules.
    Vivek S Dave et al, 2017, Drug Dev Ind Pharm CrossRef
  35. Therapeutic potential of carbohydrate-based polymeric and nanoparticle systems
    Rajesh Sunasee et al, 2014, Expert Opinion on Drug Delivery CrossRef
  36. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials
    Minnie Au et al, 2016, Biomedicines CrossRef
  37. Efficient Tumor Accumulation, Penetration and Tumor Growth Inhibition Achieved by Polymer Therapeutics: The Effect of Polymer Architectures.
    Tong Shen et al, 2017, Biomacromolecules CrossRef
  38. HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release.
    Petr Chytil et al, 2018, Macromol Biosci CrossRef
  39. In Vitro Synergistic Action of Geldanamycin- and Docetaxel-Containing HPMA Copolymer-RGDfK Conjugates Against Ovarian Cancer
    Nate Larson et al, 2014, Macromol. Biosci. CrossRef
  40. Biodegradable Polymersomes as Nanocarriers for Doxorubicin Hydrochloride: Enhanced Cytotoxicity in MCF-7/ADR Cells and Prolonged Blood Circulation
    Yanhui Chao et al, 2017, Pharm Res CrossRef
  41. null
    Daniel Merk et al, 2017 CrossRef
  42. null
    Yerra Rajeshwar, 2017 CrossRef
  43. Leveraging Physiology for Precision Drug Delivery
    Wujin Sun et al, 2017, Physiological Reviews CrossRef
  44. Enhanced anti-hepatocarcinoma efficacy by GLUT1 targeting and cellular microenvironment-responsive PAMAM–camptothecin conjugate
    Pengkai Ma et al, 2018, Drug Delivery CrossRef
  45. Anticancer effects of Ac-Phe-Lys-PABC-doxorubicin via mitochondria-centered apoptosis involving reactive oxidative stress and the ERK1/2 signaling pathway in MGC-803 cells
    YAN-JUN ZHONG et al, 2013 CrossRef
  46. Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy
    Sonja Dragojevic et al, 2015, Molecules CrossRef
  47. Metabolomics facilitates the discrimination of the specific anti-cancer effects of free- and polymer-conjugated doxorubicin in breast cancer models
    Ana Armiñán et al, 2018, Biomaterials CrossRef
  48. The expanding role of prodrugs in contemporary drug design and development
    Jarkko Rautio et al, 2018, Nat Rev Drug Discov CrossRef
  49. Nanoformulations of doxorubicin: how far have we come and where do we go from here?
    Ivana Borišev et al, 2018, Nanotechnology CrossRef
  50. null
    Junqing Wang et al, 2018 CrossRef
  51. null
    Matthew Parrott et al, 2018 CrossRef
  52. Responsive polymer conjugates for drug delivery applications: recent advances in bioconjugation methodologies
    Daniel Cristian Ferreira Soares et al, 2018, Journal of Drug Targeting CrossRef
  53. null
    Miguel Moreno Raja et al, 2019 CrossRef
  54. Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics
    Sindisiwe Mvango et al, 2018, Pharm Res CrossRef
  55. Polymer–drug conjugate therapeutics: advances, insights and prospects
    Iriny Ekladious et al, 2018, Nat Rev Drug Discov CrossRef
  56. Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases
    Divya Dheer et al, 2019, Advanced Drug Delivery Reviews CrossRef
  57. null
    Matthew Parrott et al, 2019 CrossRef
  58. null
    Katia Maso et al, 2019 CrossRef
  59. null
    Alberto Gabizon et al, 2011 CrossRef
  60. null
    Sebastien Taurin et al, 2013 CrossRef
  61. null
    Cristina Fante et al, 2013 CrossRef
  62. null
    Mitulkumar A. Patel et al, 2014 CrossRef
  63. null
    Jurjen S. Lagas et al, 2014 CrossRef
  64. null
    Anjan Kumar Mohanty et al, 2015 CrossRef
  65. GRP78‐Targeted HPMA Copolymer‐Photosensitizer Conjugate for Hyperthermia‐Induced Enhanced Uptake and Cytotoxicity in MCF‐7 Breast Cancer Cells
    Gantumur Battogtokh et al, 2019, Macromol. Biosci. CrossRef
  66. null
    Maricla Galetti et al, 2019 CrossRef
  67. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines
    Geoffrey M. Lynn et al, 2019, Cancer Letters CrossRef
  68. Modifying the Body Distribution of HPMA-Based Copolymers by Molecular Weight and Aggregate Formation
    Mareli Allmeroth et al, 2011, Biomacromolecules CrossRef
  69. null
    Mohd Jahir Khan et al, 2019 CrossRef
  70. Prodrugs as drug delivery system in oncology
    J. Delahousse et al, 2019, Cancer Chemother Pharmacol CrossRef
  71. Clinical developments of antitumor polymer therapeutics
    Shazia Parveen et al, 2019, RSC Adv. CrossRef
  72. Interaction of N-(2-Hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates with Human Liver Microsomal Cytochromes P450: Comparison with Free Doxorubicin
    Vlastimil Mašek et al, 2011, Drug Metab Dispos CrossRef
  73. Polymer-functionalized mesoporous carbon nanoparticles on overcoming multiple barriers and improving oral bioavailability of Probucol
    Hongyan Lu et al, 2019, Carbohydrate Polymers CrossRef
  74. Identification of Potential Inhibitors of Cathepsin‐B using Shape & Pharmacophore‐based Virtual Screening, Molecular Docking and Explicit Water Thermodynamics
    Tanuj Sharma et al, 2019, Mol. Inf. CrossRef
  75. A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market
    Mara Gonçalves et al, 2019, Journal of Controlled Release CrossRef
  76. null
    Mala Trivedi et al, 2020 CrossRef
  77. Identifying “Many-to-Many” Relationships Between Gene-Expression Data and Drug-Response Data Via Sparse Binary Matching
    Jiulun Cai et al, 2019, IEEE/ACM Trans. Comput. Biol. and Bioinf. CrossRef
  78. A Novel pH-Tunable Secondary Conformation Containing Mixed Micellar System in Anticancer Treatment
    Fu-Ying Shih et al, 2020, Cancers CrossRef
  79. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery
    Sarita Rani et al, 2020, International Journal of Pharmaceutics CrossRef
  80. Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
    Nataša Avramović et al, 2020, Pharmaceutics CrossRef
  81. HPMA-based polymeric conjugates in anticancer therapeutics
    Sarita Rani et al, 2020, Drug Discovery Today CrossRef
  82. Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer
    Sibusiso Alven et al, 2020, Pharmaceutics CrossRef
  83. Poly(2-methyl-2-oxazoline) conjugates with doxorubicin: From synthesis of high drug loading water-soluble constructs to in vitro anti-cancer properties
    Ondrej Sedlacek et al, 2020, Journal of Controlled Release CrossRef
  84. Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy
    Maria Raffaella Zocchi et al, 2020, Cancers CrossRef
  85. Polymer nanomedicines
    Jindřich Kopeček et al, 2020, Advanced Drug Delivery Reviews CrossRef
  86. Doxorubicin-loaded composite nanogels for cancer treatment
    Marzieh Mohammadi et al, 2020, Journal of Controlled Release CrossRef
  87. Recent developments in targeting genes and pathways by RNAi‐based approaches in colorectal cancer
    Asiyeh Jebelli et al, 2020, Med Res Rev CrossRef
  88. HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
    Melissa N. Zimel et al, 2017, Mol Cancer Ther CrossRef
  89. Polyvinyl Alcohol Carbazate as a Polymer-Based Antitumoral Agent
    Felix Sellberg et al, 2021, Front. Oncol. CrossRef
  90. Supramolecular cancer nanotheranostics
    Jiong Zhou et al, 2021, Chem. Soc. Rev. CrossRef
  91. Review of the Mechanism of Nanocarriers and Technological Developments in the Field of Nanoparticles for Applications in Cancer Theragnostics
    Nehil Shreyash et al, 2021, ACS Appl. Bio Mater. CrossRef
  92. null
    Mohammed O. Balogun et al, 2021 CrossRef
  93. Rational nanocarrier design towards clinical translation of cancer nanotherapy
    Dandan Guo et al, 2021, Biomed. Mater. CrossRef
  94. The Past, Present, and Future of Breast Cancer Models for Nanomedicine Development
    Paz Boix-Montesinos et al, 2021, Advanced Drug Delivery Reviews CrossRef
  95. Polymer−Drug Conjugates for Combination Anticancer Therapy: Investigating the Mechanism of Action
    Gianfranco Pasut et al, 2009, J. Med. Chem. CrossRef
  96. Polymer‐Based Drug‐Free Therapeutics for Anticancer, Anti‐Inflammatory, and Antibacterial Treatment
    Marina Rodrigues Tavares et al, 2021, Macromol. Biosci. CrossRef
  97. Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond
    Safikur Rahman et al, 2021, Biomedicines CrossRef
  98. Remodeling tumor microenvironment with nanomedicines
    John D. Martin et al, 2021, WIREs Nanomed Nanobiotechnol CrossRef
  99. Vinyl Polymer-based technologies towards the efficient delivery of chemotherapeutic drugs
    Patrícia Pereira et al, 2021, Progress in Polymer Science CrossRef
  100. Comparison of Hydrazone Heterobifunctional Cross-Linking Agents for Reversible Conjugation of Thiol-Containing Chemistry
    R. James Christie et al, 2010, Bioconjugate Chem. CrossRef
  101. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy
    Muhammad Sohail et al, 2021, Expert Review of Anticancer Therapy CrossRef
  102. Nanomedicines: Recent Progress, Impact and Challenges in Applications
    Aditi Singh, 2021, Asian J. Chem. CrossRef
  103. Synthesis, Morphology, and Rheological Evaluation of HPMA (N-2-Hydroxypropyl Methacrylamide)-PCL (Polycaprolactone) Conjugates
    Sarita Rani et al, 2021, ACS Omega CrossRef
  104. Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication
    Milad Rasouli et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef
  105. A modular ROS-responsive platform co-delivered by 10-hydroxycamptothecin and dexamethasone for cancer treatment
    Qingye Meng et al, 2021, Journal of Controlled Release CrossRef
  106. Current Understandings and Clinical Translation of Nanomedicines for Breast Cancer Therapy
    Yike Jiang et al, 2021, Advanced Drug Delivery Reviews CrossRef
  107. Carrier-free nanomedicines for cancer treatment
    Li-Han Liu et al, 2022, Progress in Materials Science CrossRef
  108. null
    Ruiwu Liu et al, 2011 CrossRef
  109. null
    Coralie Deladriere et al, 2011 CrossRef
  110. Tumor Stimulus-Responsive Biodegradable Diblock Copolymer Conjugates as Efficient Anti-Cancer Nanomedicines
    Vladimír Šubr et al, 2022, JPM CrossRef
  111. Increasing the Tumoricidal Activity of Daunomycin-pHPMA Conjugates Using Vitamin B12 as a Targeting Agent
    null Gregory Russell-Jones et al, 2012, J. Can. Res. Updates CrossRef
  112. Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation
    Seong Ik Jeon et al, 2022, Nano Res. CrossRef
  113. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines
    Tânia Capelôa et al, 2020, Seminars in Cell & Developmental Biology CrossRef
  114. null
    Zhiguo Wang et al, 2022 CrossRef
  115. Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
    Kyeong-Min Lee et al, 2022, Biochemical and Biophysical Research Communications CrossRef
  116. Poly(2-oxazoline) – Ferrostatin-1 drug conjugates inhibit ferroptotic cell death
    Joshua P. Morrow et al, 2022, Journal of Controlled Release CrossRef
  117. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
    Juanjuan Yang et al, 2022, Advanced Drug Delivery Reviews CrossRef
  118. Opportunities and Challenges of Switchable Materials for Pharmaceutical Use
    Deniz Ceylan Tuncaboylu et al, 2022, Pharmaceutics CrossRef
  119. null
    Ankita Dadwal et al, 2023 CrossRef
  120. null
    C. Sarath Chandran et al, 2023 CrossRef
  121. The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation
    Olga Vasiljeva et al, 2019 CrossRef
  122. Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting
    Jihoon Lee et al, 2023, Pharmaceuticals CrossRef
  123. Rational design of oral delivery nanosystems for hypoglycemic peptides
    Taoxing Peng et al, 2023, Nano Today CrossRef
  124. Exosomes as efficient platforms for delivering adenosine-tetra peptide conjugate to pancreatic cancer cells: An in vitro/in silico study
    Pardis Ahmadi et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
  125. In vitro studies of titanium dioxide nanoparticles modified with glutathione as a potential drug delivery system
    Jolanta Pulit-Prociak et al, 2023 CrossRef
  126. 10-hydroxycamptothecin-loaded starch-based microcapsules with the stepwise responsive release strategy for targeted controlled release
    Qingye Meng et al, 2023, International Journal of Biological Macromolecules CrossRef
  127. New opportunities and old challenges in the clinical translation of nanotheranostics
    Peter J. Gawne et al, 2023, Nat Rev Mater CrossRef
  128. Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome
    Jeferson Gustavo Henn et al, 2023, Journal of Drug Delivery Science and Technology CrossRef